⌕
MapLight Therapeutics · MPLT · Nasdaq
Tenet 74 · Solid
Compare
$6.90−4.83%At closeTenet 74 · Solid
$6.90−0.35 (−4.83%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

MapLight Therapeutics (MPLT) Stock

MapLight Therapeutics (MPLT) closed at $6.90 on Nov 16, 2026; its Tenet Score is 74 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$6.90
Nov 16, 2026
Market cap
$313.5M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
6.06 – 40.43
low → high
Tenet Score
74/100
Solid · 409 Healthcare peers

Industry: Pharmaceutical Preparations · see every company filed here →

MapLight Therapeutics Inc. scores 74/100. Solid. Strongest on value and financial health, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 74 is built from 3 of 4 pillars, from 40% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
74/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
97
Quality
32
Health
92
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueA+QualityDHealthAGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
0.7×
cap ÷ fiscal 2025 book value, Nov 13, 2026 close
P/S
—
no P/S on file
ROE
−56%
fiscal 2025
Operating margin
—
no operating margin on file
Net margin
—
Not reported in the company's filings for this period.
Current ratio
20.01
fiscal 2025
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About MapLight Therapeutics Inc.

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to add…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 32 US ETFs · top wrappers by weightSee all ETFs holding MPLT →

Similar-sized companies in Pharmaceutical Preparations

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is MapLight Therapeutics in?

MapLight Therapeutics is in the Healthcare sector and the Pharmaceutical Preparations industry.

What is MapLight Therapeutics' Tenet Score?

MapLight Therapeutics' Tenet Score is 74 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.